Saturday 17 October 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
2.83
0.01
+0.35%
Follow SCLX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.70 | 0.84 | 2.77 | 3.52 | |
P/FCF ratio |
0.00 | 0.00 | 22.96 | 5.97 | |
P/Operating CF |
(7.98) | (25.83) | (4.80) | 17.27 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.27 | 3.16 | 5.19 | 4.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.89) | (32.40) | 41.14 | 7.88 | |
EV/FCF |
(7.57) | (30.88) | 42.97 | 7.89 | |
Quick Ratio |
0.01 | 0.03 | 0.05 | 0.04 | |
Current Ratio |
0.07 | 0.08 | 0.08 | 0.05 | |
Net Debt/EBITDA |
(3.13) | (2.74) | (2.02) | (0.24) | |
Debt/Assets |
31.87% | 27.51% | 22.81% | 16.56% | |
Debt/Equity |
(0.26) | (0.32) | (0.39) | (0.25) | |
Asset Turnover |
0.19 | 0.18 | 0.13 | 0.21 | |
Operating CF/Net income |
0.06 | 0.03 | 0.53 | (0.03) | |
Capex/Depreciation |
(0.15) | (0.74) | 0.00 | 0.00 | |
Interest Coverage |
(4.82) | — | (18.58) | (66.66) | |
Research and Development Expense of Revenue |
43.65% | 37.27% | 170.42% | 36.92% | |
Selling, General and Administrative Expense of Revenue |
365.87% | 360.30% | 629.23% | 1,788.11% | |
Intangible Assets out of Total Assets |
0.50 | 0.47 | 0.38 | 0.87 | |
Share Based Compensation of Revenue |
62.27% | 42.13% | 117.73% | 30.83% | |
Graham Net Nets |
(9.82) | (17.68) | (6.42) | (3.09) | |
Graham Number |
224.45 | 183.23 | 125.46 | 88.56 | |
Earnings Yield |
(637.18%) | (975.18%) | (479.61%) | (183.73%) | |
Free Cash Flow Yield |
(33.15%) | (12.10%) | 4.36% | 16.74% | |
Revenue per Share |
1.11 | 1.25 | 0.43 | 0.91 | |
Operating CF per Share |
(0.98) | (0.16) | (1.58) | 0.71 | |
Capex per Share |
(0.08) | (0.42) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.06) | (0.58) | (1.60) | 0.71 | |
Cash per Share |
0.08 | 0.49 | 1.00 | 0.08 | |
Shareholders Equity per Share |
(45.05) | (36.87) | (19.19) | (15.49) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(45.05) | (36.87) | (19.19) | (15.49) | |
Free Cash Flow |
(7.31) | (4.01) | (17.60) | 8.23 | |
Working Capital |
(476.01) | (459.78) | (445.29) | (342.46) | |
Capital Expenditures |
(0.58) | (2.90) | (0.13) | — | |
Net Current Asset Value |
(527.81) | (505.73) | (538.37) | (439.11) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.34 | 0.03 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.60 | 10.63 | 20.84 | 21.76 | |
Average Payables |
90.10 | 79.42 | 69.44 | 55.38 | |
Average Inventory |
3.35 | 3.77 | 3.61 | 1.74 | |
Average Assets |
168.66 | 186.31 | 228.97 | 188.15 | |
Average Common Equity |
(279.74) | (232.78) | (202.20) | (195.52) |
Columns are period end dates